Oxford University says preliminary testing suggests that it is a vaccine developed with AstraZeneca that protects against coronavirus viruses first found in the UK.
Oxford researchers have stated that the COVID-19 vaccine from Oxford University and Azterazeneca have similar efficacy against the British coronavirus virus.
The university, which developed the jab with a British-Swedish pharmaceutical firm, said a continued evaluation of its effectiveness showed that, according to preliminary testing, it has “similar efficacy” to other coronovirus strains.
“Data from our trials in the United Kingdom … indicate that the vaccine not only avoids the original pandemic virus, but also the novel version,” said Andrew Pollard, co-chief investigator on the Oxford vaccine trial.
The university said the analysis, which relies on samples taken between October and mid-January, also indicated that the shot had a “short duration of shedding and viral load”, which could decrease the transmission of the virus. .
Preliminary findings, which still need to be peer reviewed, are the first to report on the efficacy of the Oxford-AstraZeneca vaccine against new variants, it noted.
The first identified version could be more easily broadcast in Kent in southern England, prompting several countries to restrict travel to the UK.
This led to the spread of a new national lockdown in England last month.
The lockdown came when the UK began rolling out the AstraZeneca vaccine. More than 10 million people have received their first dose of AstraZeneca or one of Pfizer’s shots.
Britain said it was believed that the vaccines were effective against variants that are roaming the UK.
Vaccine co-developer Sarah Gilbert stated that, although the vaccine had efficacy against UK variants, it may need to be adapted for future variants.
“We are working with AstraZeneca to optimize the pipeline required for a strain change,” Gilbert said.